Earlier today LIDDS announced that they have received freedom to operate regarding their new TLR9 agonist project, according to an analysis carried out. This puts LIDDS in a position where they have the right to develop their reformulated TL9 agonist without a collaboration agreement and have the right to license out their project in the future.